The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract]

Gale, Rosemary, Hills, Robert Kerrin, Green, Claire, Patel, Yashma, Gilkes, Amanda F., Lazenby, Michelle, Wheatley, Keith, Linch, David C. and Burnett, Alan Kenneth 2008. The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract]. Blood -New York- 112 (11) , p. 207.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Additional Information:	50th Annual Meeting of the American-Society-of-Hematology Location: San Francisco, CA Date: DEC 06-09, 2008
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	19 Oct 2019 02:58
URI:	http://orca.cf.ac.uk/id/eprint/49826

Actions (repository staff only)

Edit Item